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Objective: The BCL2 family proteins are critical mediators of cellular apoptosis and, as such, have been implicated as determinants of 
cancer cell chemo-sensitivity. Recently, it has been demonstrated that the phosphorylation status of the BCL2 antagonist of cell 
death (BAD) protein may influence ovarian cancer (OVCA) cell sensitivity to cisplatin. Here, we sought to evaluate how kinase 
and phosphatase components of the BAD apoptosis pathway influence OVCA chemo-sensitivity.
Methods: Protein levels of cyclin-dependent kinase 1 (CDK1) and protein phosphatase 2C (PP2C) were measured by immuno-
fluorescence in a series of 64 primary advanced-stage serous OVCA patient samples. In parallel, levels of cAMP-dependent protein 
kinase (PKA), AKT, and PP2C were quantified by Western blot analysis in paired mother/daughter platinum-sensitive/resistant 
OVCA cell lines (A2008/C13, A2780S/A2780CP, Chi/ChiR). BAD pathway kinase CDK1 was depleted using siRNA transfection, and 
the influence on BAD phosphorylation and cisplatin-induced apoptosis was evaluated.
Results: OVCA patient samples that demonstrated complete responses to primary platinum-based therapy demonstrated 4-fold 
higher CDK1 (p<0.0001) and 2-fold lower PP2C (p=0.14) protein levels than samples that demonstrated incomplete responses. Protein 
levels of PP2C were lower in the platinum-resistant versus that shown in the platinum-sensitive OVCA cell line sub-clones. Levels 
of PKA were higher in all platinum-resistant than in platinum-sensitive OVCA cell line sub-clones. Selective siRNA depletion of CDK1 
increased sensitivity to cisplatin-induced apoptosis (p<0.002).
Conclusion: BAD pathway kinases and phosphatases, including CDK1 and PP2C, are associated with OVCA sensitivity to platinum 
and may represent therapeutic opportunities to enhance cytotoxic efficacy.
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INTRODUCTION
The development of chemo-resistance has a dramatic influence 
on survival for patients with ovarian cancer (OVCA). Although 
patients with OVCA demonstrate remarkable sensitivity to plati-
num-based chemotherapy during primary therapy, the major-
ity of patients eventually develop recurrent or persistent dis-
ease that becomes resistant to platinum-based treatment [1,2]. 
Patients with platinum-resistant disease are treated with a se-
lection of agents, including pegylated liposomal encapsulated 
doxorubicin, topotecan, taxanes, gemcitabine, etoposide, and 
cyclophosphamide [1-3]. Despite this array of available drugs, 
once platinum resistance has developed, few active therapeu-
tic options exist and patient survival is generally short-lived [3]. 
In this context, platinum resistance is frequently viewed as a 
surrogate marker for more generic chemo-resistance. As such, 
targeted therapies that enhance cancer cell sensitivity to cy-
totoxic agents offer significant potential to improve outcome. 
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Although changes in cellular drug efflux, increased cellular 
glutathione levels, increased DNA repair, and drug tolerance 
have all been shown to contribute to platinum-resistance, the 
fundamental mechanisms that drive OVCA chemo-resistance 
remain to be completely defined [4-6]. 
Recently, it has been suggested that cisplatin-induced DNA 
damage leads to phosphorylation of the BCL2 antagonist of cell 
death (BAD) protein at the serine-112 and serine-136 residues 
and that inhibition of phosphorylation at these sites (via inhi  bi-
tion of ERK and/or AKT pathways) increases OVCA cell sen  si  tivity 
to cisplatin- and paclitaxel-induced apoptosis [7,8]. In light of 
these findings, in this study, we sought to further cha  racterize 
the role of a series of BAD-apoptosis pathway phosphatases and 
kinases as determinants of OVCA chemo-sensitivity. We therefore 
examined the association of key BAD pathway protein kinases 
and phosphatases with OVCA cells in vitro and examined the 
chemo-resistance of these kinases and phosphatases in in vivo 
OVCA samples and also evaluated the pathway as a potential 
therapeutic target to increase OVCA cell response to cisplatin. 
MATERIALS AND METHODS
1. Cell line cultures
Cell lines C13, A2780S, A2780CP, A2008, Chi, and ChiR were 
kindly provided by Dr. Patricia Kruk (Department of Pathol-
ogy, University of South Florida College of Medicine, Tampa, 
FL, USA). Cell lines were cultured in RPMI-1640 supplemented 
with 10% fetal bovine serum, 1% sodium pyruvate, and 1% 
nonessential amino acids and maintained at 37
oC, 5% CO2. All 
tissue culture reagents were obtained from Sigma Aldrich (St. 
Louis, MO, USA). 
2. Patient samples
We evaluated 64 advanced-stage (stage III/IV) serous epithelial 
OVCA samples, resected at the time of primary surgery, from 
patients who went on to receive platinum-based primary therapy. 
All tissues were collected under Internal Review Board-approved 
protocols and with written informed patient consent. Samples 
were subjected to histopathologic review by a gynecologic 
on  cology pathologist to confirm diagnosis and to confirm 
greater than 70% tumor content, before being fixed in forma-
lin and embedded in paraffin. Response to therapy was evalu-
ated from the medical record by a single gynecologic oncologist 
using standard criteria for patients with measurable disease, 
based upon WHO guidelines [9]. CA-125 was used to classify 
responses only in the absence of a measurable lesion; CA-
125 response criteria were based on established guidelines 
[10,11]. A complete response (CR) was defined as a complete 
disappearance of all measurable and assessable disease or, in 
the absence of measurable lesions, a normalization of the CA-
125 level following adjuvant therapy. An incomplete response 
(IR) was classified as patients who demonstrated only a partial 
response, had no response, or progressed during primary the  ra-
py. A partial response was considered a 50% or greater reduc-
tion in the product obtained from measurement of each bi-
di  mensional lesion for at least 4 weeks or a drop in the CA-125 
level by at least 50% for at least 4 weeks. Disease progression 
was defined as a 50% or greater increase in the product from 
any lesion documented within 8 weeks of initiation of therapy, 
the appearance of any new lesion within 8 weeks of initiation 
of therapy, or any increase in the CA-125 level from baseline 
at initiation of therapy. Stable disease was defined as disease 
not meeting any of the above criteria. Forty-one OVCA patient 
samples demonstrated a CR and 23 showed an IR to primary 
platinum-based therapy following surgery. 
3. Immunofluorescence microscopy
Slides were de-paraffinized and rehydrated using xylene and 
then subjected to serial dilutions of ethanol. Slides then under-
went heat-induced epitope retrieval by incubation in Tris-EDTA 
buffer (10 mM Tris base, 1 nM EDTA, 0.05% Tween 20, pH 9.0) 
for 20 minutes at 100
oC. Slides were washed in phosphate-bu-
ffered saline (PBS), incubated in blocking serum (0.3% Triton 
X-100, 0.1% normal goat serum in PBS) for 1 hour at room 
tem  perature, and exposed to primary antibody in blocking se-
rum for 48 hours at 4
oC. Slides were washed 3 times in PBS, in-
cubated with fluorescent-labeled secondary antibody in blo-
cking serum for 2 hours at room temperature, counterstained, 
and mounted with Prolong Gold containing DAPI (Invitrogen, 
Grand Island, NY, USA). Images were acquired as TIFF files using 
the Zeiss Axio Imager Z1 (Carl Zeiss Inc., Jena, Germany) auto-
mated fluorescent scope and analyzed for percent expre  ssing 
cells using Image Pro Plus software.
4. Western blot analysis
Cells were harvested in media using a Cell Lifter (Thermo-Fisher, 
Suwanee, GA, USA) and then washed with cold PBS, and lysates 
prepared with SDS lysis buffer (2% SDS, 10% gly  ce  rol, 0.06 M 
Tris, pH 6.8). Lysates were evaluated for protein concentration 
using the BCA method (Pierce, Rockford, IL, USA). Proteins (50 
µg) were separated on 10% SDS-PAGE gels and transferred to 
nitrocellulose membranes. Membranes were blocked in Tris-
buffered saline containing 0.05% Tween 20 (TBST)-5% nonfat 
milk and incubated with primary antibody in TBST-5% nonfat 
milk overnight at 4
oC. Membranes were washed three times 
for 10 minutes with TBST and incubated with the appropriate 
secondary antibody in TBST-5% non-fat milk for 90 minutes at BAD kinase CDK1 and phosphatase PP2C and ovarian cancer
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room temperature. Antibody binding was visualized by che-
miluminescence on autoradiography film. 
5. Transfection of siRNA
RNA duplexes for BAD (catalog no. s1861) were purchased 
from Applied Biosystems Inc. (Foster City, CA, USA), and cyclin-
dependent kinase 1 (CDK1; catalog no. 6376) was purchased 
from Cell Signaling Technology (Boston, MA, USA). Cells were 
transfected by electroporation using the Nucleofector trans-
fection kit according to manufacturer’s recommendations 
(Amaxa, Gaithersburg, MD, USA). Cells (4×10
6) were suspend-
ed in 0.1 mL electroporation buffer V containing 1 µM siRNA 
and pulsed using program X-001. Pulsed cells were resuspen-
ded in 0.5 mL of complete media without antibiotics and 
incubated at 37
oC for 15 minutes before experimentation. The 
Silencer negative control no. 2 siRNA (catalog no. 4390846, 
ABI), a nonsense siRNA duplex, was used as a control. A2780S 
was selected based upon our significant experience with it as 
a model for chemosensitivity and for functional analyses asso-
ciated with targeted therapeutic interventions. 
6. Apoptosis assay
Percent apoptotic nuclei were determined by morphologic 
assessment of condensed chromatin and fragmented DNA. 
Cells were harvested in media using a Cell Lifter (Thermo-Fisher, 
Suwanee, GA, USA), washed with cold PBS, and fixed in 4% 
paraformaldehyde for 10 minutes at room temperature. Cell 
nuclei were stained with 0.5 µg/mL of bis-benzimide trihydro-
chloride (Hoechst 33258, Molecular Probes, Eugene, OR, USA) 
and evaluated by fluorescence microscopy. Two hundred cells 
were counted per condition and scored for apoptosis (nuclei/
all nuclei ×100). Each experiment was repeated at least in 
triplicate. Error bars were used to indicate standard deviation.
7. Statistical analysis
Differences in protein levels were evaluated using Student’s t-
test. A p-value of less than 0.01 was defined as indicating a sta-
tistically significant difference between CR and IR or between 
cisplatin-sensitive and cisplatin-resistant cell lines.
RESULTS
1. Expression levels of CDK1 and PP2C are associated with 
OVCA patient response to primary platinum-based therapy
The influences of kinases that phosphorylated BAD at serine 
-112, -136, and -155 in the sensitivity of OVCA to chemothera-
py are well established. However, the role of the BAD protein 
phosphatase, PP2C, and the BAD protein kinase, CDK1, which 
acts at -128, is controversial (some studies suggesting it is an-
Fig. 1. Cisplatin-resistant tumor samples express higher levels of BCL2 antagonist of cell death (BAD) pathway kinases and lower levels of BAD 
pathway phosphatases. Protein levels of the BAD pathway cyclin dependent kinase 1 (CDK1) (A) and protein phosphatase 2C (PP2C) (B) were 
evaluated by immunofluorescence in 64 primary ovarian cancer samples from tumors that demonstrated a complete response (CR, 41) or 
incomplete response (IR, 23) to primary platinum therapy. Error bars depict the standard error of the mean.Nisha Bansal, et al.
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ti-apoptotic, and some the opposite). We therefore sought to 
explore the role of CDK1 as well as PP2C in OVCA chemosen-
si  tivity. The relationships between the expression levels of BAD 
pathway kinase (CDK1) and BAD protein phosphatase 2C (PP2C) 
and OVCA chemosensitivity were examined in 64 primary OVCA 
patient samples using immunofluorescence analysis. OVCA 
samples demonstrating IR to primary platinum-based therapy 
had four-fold higher CDK1 levels (p<0.0001) than OVCAs dem-
onstrating CR (Fig. 1A). In contrast, the PP2C levels were two-
fold lower in IR than in CR samples (p=0.14) (Fig. 1B).
2. Expression levels of BAD kinases and phosphatases are 
associated with OVCA in vitro sensitivity to cisplatin
Western blot analysis revealed that the platinum-resistant 
OVCA cells (ChiR and C13) exhibited lower expression levels 
PP2C (serine-155) than the corresponding platinum-sensitive 
Fig. 2. (A) Western blots showing the relative expression of AKT, phosphorylated AKT (pAKT), PKA, and phosphorylated PKA (pPKA), PP2C, and 
BCL2 antagonist of cell death (BAD) in the paired cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines: Chi/ChiR, A2780S/A2780CP, 
A2008/C13. The expression of GAPDH served as a loading control for each paired cell line. (B) densitometry analysis of the Western blots for 
each sensitive/resistant cell line pair, where square pixel surface area for each band was normalized to GAPDH expression. Relative protein 
expression between sensitive and resistant cell line pairs is presented as a percentage of the sensitive cell line.BAD kinase CDK1 and phosphatase PP2C and ovarian cancer
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parental clones (Chi and A2008) (Fig. 2). Consistently, levels of 
phospho-cAMP-dependent protein kinase (PKA), as a fraction 
of total PKA, were higher in all platinum-resistant sub-clones 
(ChiR, A2780CP, and C13) versus that shown in the platinum-
sensitive parental lines (Fig. 2). Levels of activated phospho-
AKT (as a fraction of total AKT) were higher in platinum-resis-
tant daughter cells (A2780CP and C13) than in their platinum-
sensitive parental lines (Fig. 2), although both the Chi and 
ChiR cell lines expressed very low levels of phospho-AKT. 
3. Modulation of BAD pathway protein expression
The effect of BAD pathway kinases and phosphatases on 
platinum sensitivity may be mediated through the regulation 
of BAD protein expression or via post-translational modifica-
tion, such as phosphorylation. To determine the contribution 
of BAD protein expression to OVCA cell line platinum sensitiv-
ity, levels of BAD were depleted using siRNA (Fig. 3A). Deple-
tion of BAD protein significantly increased the percentage of 
apoptotic nuclei both in the presence and absence of cisplatin 
when compared to cells transfected with the non-targeting 
siRNA (p=0.02 and p=0.02, respectively) (Fig. 3B). 
To further determine the influence of BAD post-translational 
phosphorylation on OVCA sensitivity to cisplatin, we evalu-
ated the effect of CDK1 depletion by siRNA. The OVCA cell line 
A2780S was subjected to transfection with siRNAs to CDK1 
in the presence and absence of cisplatin, and the effect on 
cisplatin-induced cell death (Fig. 4A) was evaluated. After 48 
hours of cisplatin treatment, A2780S cells depleted of CDK1 
showed a significant increase in the percentage of apoptotic 
nuclei (p<0.002, respectively) (Fig. 4B).
DISCUSSION
Few clinical or biologic events impact patient outcome more 
than the development of resistance to chemotherapy. Although 
only 30% of patients with advanced-stage epithelial OVCA have 
de novo (intrinsic) platinum-resistant disease at diagnosis, even-
tually the majority will develop acquired resistance to pla  tinum-
based regimens. The presence of such platinum-resistant di  se  a  se 
Fig. 3. BCL2 antagonist of cell death (BAD) protein depletion increases 
cisplatin sensitivity. The OVCA cell line A2780S was evaluated for 
BAD protein levels by Western blot (A) and apoptotic nuclei in the 
presence of cisplatin after depletion of BAD protein by siRNA (B). 
GAPDH served as a protein loading control. A non-targeting (NT) 
siRNA served as a negative transfection control. Errors bars depict the 
standard error of the mean.
Fig. 4. Depletion of cyclin-dependent kinase 1 (CDK1) protein 
increases cisplatin sensitivity. The OVCA cell line A2780S was 
transfected with a non-targeting (NT) siRNA or siRNA specific to CDK1 
and evaluated for protein expression by Western blot analysis (A) and 
percent apoptotic nuclei in the presence of cisplatin (B). GAPDH was 
used as a protein loading control. Error bars indicate standard error of 
the mean.Nisha Bansal, et al.
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is frequently viewed as a clinical biomarker that pre  dicts low 
li  ke  li  hood of response to other cytotoxic agents, short disease-
free intervals, and poor overall survival. Several studies have 
sought to determine the molecular determinants of chemo-
re  si  stance [12-15]. However, to date, a comprehensive under-
standing of the genes, molecular pathways and the post-trans-
lational events that may influence chemo-resistance re  mains 
elusive. Jazaeri et al. [14] have suggested that the mole  cular 
pathways that govern intrinsic resistance to primary therapy 
may be different from the pathways activated during acquired 
chemo-resistance. In contrast, a study by Kim et al. [16] found 
significant similarities in gene expression signatures derived 
from intrinsic resistant and acquired resistant tumors samples. 
These contrasting findings underscore the molecular hetero-
geneity of cancer development and response to chemothera-
py. Using cell line models of chemoresistance, we and others 
have found that aberrant regulation of apoptosis to be associ-
ated with the development of chemoresistance [17,18]. 
Apoptosis is controlled in part by the BCL2 family of proteins 
which include the pro-apoptotic (e.g., Bcl-xS, BAD, Bax, Bak) and 
anti-apoptotic (e.g., Bcl-2, Bcl-xL, MCL-1, A1, BAG-1) family mem-
bers [19-22]. BAD is known to hetero-dimerize with Bcl-xL and 
Bcl-2 but not with Bcl-xS, Bax, A1, or Mcl-1. Dimerization of BAD 
with Bcl-xL results in displacement of Bax and an increase in 
mitochondrial  membrane  permeability,  which  induces  apop  tosis 
[23]. BAD is regulated by phosphorylation at three pri  mary sites, 
including serine-112, -136, and -155. When BAD is phosphory-
lated, it is unable to heterodimerize with Bcl-2 or Bcl-xL, such 
that Bcl-xL is released to bind Bax, inhibiting apoptotic function 
[23]. In this way, BAD phosphorylation status influences Bax dis-
placement from Bcl-xL and ability to induce cell death. BAD 
phosphorylation at serine-136 is induced by protein ki  nase B 
(AKT) [24]. BAD serine-112 is phosphorylated by mitogen-ac-
ti  vated protein kinase-activated protein kinase-1 (also called 
RSK) and PKA, and BAD serine-155 is phosphorylated by PKA, 
which also inhibits Bcl-xL binding [25-27]. Phosphatases PP1, 
PP2A, and PPM1 (PP2C/PPM1A), and calcineurin have pro-apop-
to  tic effects believed to be influenced by the de-phos  phory  la  tion 
of BAD [28,29]. In light of data supporting a role for BAD phos-
phorylation status in determination of apoptosis and survival 
[30,31], we sought to explore the possibility that BAD pathway 
kinases and phosphatases that influence BAD phosphorylation 
may not only influence OVCA cisplatin sensitivity but may 
re  present therapeutic targets to increase human cancer cell 
sensitivity to cisplatin and other cytotoxic agents. 
We demonstrated differential levels of BAD pathway kinase 
and phosphatase protein levels in platinum-sensitive and 
platinum-resistant patient samples and cell lines. Our results 
provide further support for the association between BAD 
pathway activity and chemotherapy resistance, likely via phos-
phorylation of the BAD protein. Although levels of BAD pro-
tein are similar between platinum-sensitive parental lines and 
their platinum-resistant sub-clones, siRNAs to the BAD gene 
induced an increase in apoptosis, both in the presence and 
absence of cisplatin. Using siRNAs to CDK1, a kinase that phos-
phorylates BAD, we were able to demonstrate an increase 
in cisplatin-induced apoptosis. It is unclear from these data 
whether absolute levels of BAD, versus the proportion of BAD 
that is phosphorylated, dominate the balance between cellu-
lar survival and apoptosis, and also whether the effect is driven 
by changes to BAD phosphorylation at the serine-128 site, or 
by CDK1 effects on cell cycle. It is noteworthy that our analy-
sis focuses on relative differences in expression/protein level 
between chemo-sensitive and – resistant tissues in a qualita-
tive fashion. If PP2C and CDK1 are to be further explored as 
biomarkers of response, criteria for positivity will need to be 
established, requiring more quantitative future studies. We 
also recognize that the low absolute levels of expression may 
make such studies challenging and limit the potential utility of 
these markers in clinical practice. Our data demonstrate that 
the relative levels of differential expression of BAD kinases and 
phosphatases vary between cell line pairs (Fig. 2), appearing 
more evident in Chi/Chi-cisR and 2008/C13 than in A2780S/
CP cell line pairs. These data suggest that, although the BAD 
pathway is important in determination of cisplatin-induced 
apoptosis, likely via the phosphorylation status of the BAD 
protein, there are multiple other molecular mechanisms that 
underlie OVCA chemo-sensitivity and also by which changes 
in BAD phosphorylation can occur. This also further under-
scores the previously recognized molecular heterogeneity of 
ovarian cancer development and response to therapy. Our 
findings underscore the complexity of the role of the BCL2 
family of proteins in cell survival and apoptosis, as well as the 
pro- versus anti-apoptotic influence of the BAD serine-128 
site. BAD expression levels and also post-translational events 
likely influence OVCA cell apoptotic signaling and subsequent 
sensitivity to cytotoxic challenges. Our data provide additional 
evidence to support an important role for the BAD apoptotic 
pathway not only as a potential biomarker of OVCA chemo-
resistance but also as an appealing therapeutic target.
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